Pharmaxis' partner has funded US$22 million of the expected US$26 million trial cost.
Showing 25 of 847
Pharmaxis is becoming a more enticing target for drug acquisition and partnerships.
Cellmid recorded a 79% increase in hair loss product sales.
The commencement of the trial will trigger a milestone payment.
Anteo Diagnostics will receive a grant of €1.4 million.
Cellmid has recently launched its évolis® hair loss products into the U.S. market.
Regeneus (ASX:RGS) has received its US$5.5 million upfront payment from AGC for the exclusive rights to manufacture Progenza in Japan.
Regeneus is an emerging leader in cell-based medicines.
Cellmid receives vote of confidence from Australian government.
Progenza is a patented off-the-shelf stem cell technology.
CardioCel is becoming a surgeon-preferred biomaterial for heart valve repair.
Cellmid to date has derived over $1.2 million from the midkine diagnostics license.
Zelda has been re-rated in recent weeks as the company continues to deliver on milestones.
Zelda was spun out of a successful U.S. based medicinal cannabis group - Aunt Zelda’s.
Zelda reports positive results of its initial proof of concept study.
Cellmid has two business segments, consumer health and its midkine (MK) portfolio.
Mergers and acquisitions are increasing in the fibrosis and NASH space.
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
Anteo Group is a global nano-chemistry technology and medical supply group.
OncoSil Medical Ltd has been receiving a lot of broker attention recently.
Products will be targeting the US$3.5 billion hair loss market in the U.S.
Cellmid Ltd has received commitments to raise $3 million.
Admedus continues to implement numerous cost savings and has made significant improvements in its sales and marketing globally.
OncoSil Medical Ltd (ASX:OSL) ended the September quarter with $13.8 million in cash, and during the period delivered milestones.
Admedus Ltd has produced positive headline results.